Background. Cholera spread to Latin America in 1991; subsequently, cholera vaccination was considered as an interim intervention until long-term solutions involving improved water supplies and sanitation could be introduced. Three successive summer cholera outbreaks in northern Argentina and the licensing of the new single-dose oral cholera vaccine, CVD 103-HgR, raised questions of the cost and benefit of using this new vaccine. Methods. This study explored the potential benefits to the Argentine Ministry of Health of treatment costs averted, versus the costs of vaccination with CVD 103-HgR in the relatively confined population of northern Argentina affected by the cholera outbreaks. Water supplies and sanitation in this area are poor but a credible infrastructure for vaccine delivery exists. Results. In our cost-benefit model of a 3-year period (1992-1994) with an annual incidence of 2.5 case-patients per 1000 population and assumptions of vaccine efficacy of 75% and coverage of 75%, vaccination of targeted high risk groups would prevent 1265 cases. Conclusion. Assuming a cost of US$602 per treated case and of US$1.50 per dose of vaccine, the total discounted savings from use of vaccine in the targeted groups would be US$132 100. The projected savings would be altered less by vaccine coverage (range 75-90%) or efficacy (60-85%) changes than by disease incidence changes. Our analysis underestimated the true costs of cholera in Argentina because we included only medical expenditures; indirect losses to trade and tourism had the greatest economic impact. However, vaccination with CVD 103-HgR was still cost-beneficial in the base case.
The seventh pandemic of cholera reached Latin America in 1991. 1 In Argentina, the first cases were identified in February 1992 in the north 2 where outbreaks continued during the next two summers. In late 1994, the Argentine regulatory agency licensed the new live oral cholera vaccine, CVD 103-HgR. Questions then arose as to what segment of this population might be immunized.
Of the cholera cases that have occurred in Argentina, 94% were in the northern provinces of Salta and Jujuy. 3 The populations of Salta and Jujuy are culturally and socioeconomically diverse. 2, 4 In Salta and Jujuy, cholera has been virtually confined to indigenous people and migrants who live under marginal conditions and make their livelihood as agricultural workers. [5] [6] [7] Their working conditions in the fields are characterized by even fewer basic necessities than in their ramshackled homes. In considering methods of cholera control in Argentina, one must scrutinize the epidemiology of cholera among these workers.
The repetitive outbreaks of cholera in a limited proportion of the population of northern Argentina and the licensing of CVD 103-HgR prompted a cost-benefit analysis. We consider only treatment costs directly borne by the Ministry of Health; not considered are the substantial economic losses to tourism and agricultural exports during the cholera epidemics of 1992-1994.
MATERIALS AND METHODS
The population at greatest risk of contracting cholera was determined for the three cholera outbreaks in Argentina. A conservative level of vaccine coverage and efficacy and the incidence rate in this population were used in the base case. The actual medical cost of the three cholera outbreaks in these areas was calculated. An estimate of vaccine costs was determined. These expenditures were used to calculate the medical costs of the base case with and without vaccination for a hypothetical 3-year period. Sensitivity analyses were performed using additional incidence rates and a range of vaccine coverages and vaccine efficacies.
Cholera Disease Burden in Salta and Jujuy
In the summers of 1992 through 1994, cholera appeared in northern Argentina in the provinces of Salta and Jujuy. The first outbreak evolved from weeks 8-26 in 1992; the second occurred from week 50 in 1992 through week 19 in 1993; the third extended from week 40 in 1993 through week 11 of 1994. The incidence of cholera in Salta and Jujuy was calculated using case numbers and census data provided by the provincial health ministries. 4, [8] [9] [10] [11] [12] Where possible, case data were analysed by age group (0-4, 5-9, 10-14, and Ͼ14 years) and sex.
Salta. The cholera outbreak in the summer of 1992 struck three of the 23 departments of Salta: San Martin, Oran and Rivadavia. 8, 11 Data from Rivadavia were deemed unreliable (all cases of diarrhoea were reported as cholera without bacteriological confirmation) (Carmen M de Arquiza, Direccion de Epidemiologica, Salta, November 1994) and excluded from further analysis; in San Martin and Oran, bacteriological isolation of Vibrio cholerae 01 was required. The second and third cholera outbreaks, in the summers of 1993 and 1994, affected, besides San Martin and Oran, three additional departments (General Guemes, Cerrillos and Chicoana). [9] [10] [11] Therefore, a total of 1819 cases of cholera were reported in Salta, with 89% occurring in San Martin (N = 1011) and Oran (N = 614). Overall, individuals Ͼ14 years old comprised 77% of all cases; 57% were male. The incidence rates in San Martin and Oran during the three successive outbreaks are shown in Table 1 ; the mean yearly attack rate for San Martin for the 3 years was 4.6 cases per 1000 population Ͼ14 years of age; and, for Oran it was 2.0 per 1000.
Jujuy. Jujuy was affected by the cholera outbreaks in 1993 and 1994. As in Salta, cholera was limited geographically, being confined to only eight of the 16 administrative areas of the province (Yavi, San Pedro, Santa Barbara, El Carmen, Ledesma, Humahuaca, Tilcara and Tumbaya). Age-specific data are not available for the 1993 outbreak in Jujuy. However, during the summer 1994 outbreak, 250 of the 267 cases (94%) were individuals Ͼ14 years of age; 69% of these were males (Table 1) .
In summary, most cholera cases in Argentina were confined to a few northern departments (Salta) or areas (Jujuy) where the disease clustered in agricultural In the cholera regions within Salta and Jujuy, approximately 80% of the population is comprised of permanent residents and 20% of temporary workers, coming from Bolivia for each new harvest. 4, 13 We therefore assume the 20% migrant population represents an entirely new agricultural worker cohort each year. We estimate that there are 239 782 permanent agricultural workers, at risk for three successive summers, who will serve as targets for vaccination. In addition, each summer harvest season would bring an additional 59 946 temporary inhabitants (a total of 179 838 for the three successive years). Thus, 100% coverage of this population would require a total of 419 620 doses of vaccine. We also assumed only minor side-effects from vaccination.
Base Case Model
In our base case model, the annual incidence is 2.5 per 1000 population Ͼ14 years of age, approximating the actual incidence observed in Salta and Jujuy during 1992-1994 of 2.7 per 1000. We used conservative estimates of vaccine coverage and vaccine efficacy of 75% and 75%, respectively.
Sensitivity Analysis
In our sensitivity analysis, we consider annual incidence rates of 1.5, 2.0 and 3.0 per 1000 population Ͼ14 years of age; therefore, during the 3 years in this population a total of 1349-2698 cholera cases would occur ( Table 2) . We assume 75-90% vaccine coverage in this population. Several sources make us confident that such levels could be achieved. In northern Argentina, the Expanded Program on Immunization (EPI) calculates that 93% of infants are immunized.
14 The agricultural workers are greatly concerned about cholera as an occupational hazard and therefore are strongly motivated to co-operate with a vaccination programme. We assume a range of vaccine efficacy from 60% to 85% based on results of volunteer challenge studies. 15.16 In these controlled trials, a single dose of CVD 103-HgR conferred 100% protection for moderate/severe cholera following a challenge with V. cholerae of either Inaba or Ogawa serotype or either El Tor or classical biotype. The protection remained undiminished after 6 months (the longest interval tested). 15 We assume that the CVD 103-HgR vaccine, derived from classical biotype V. cholerae, confers similar levels of efficacy for 3 years. The infection-derived immunity elicited by wild type V. cholerae 01 of classical biotype persists for at least 33-36 months in volunteers. 17 Moreover, an initial episode of cholera caused by the classical biotype confers a high level (90-100%) of long-lived protection against subsequent cholera due to either the classical or El Tor biotype. 18, 19 However, to account for some degree of waning in immunity, we examined vaccine efficacies as low as 60% for the 3-year period. 
Estimation of Costs of Treatment of Cholera in Salta and Jujuy
The actual medical cost of the three cholera outbreaks for Salta and Jujuy are calculated from expenses accrued by the Ministries of Health of the two provinces. 8, 9, 20 The number (and duration) of hospitalized cases and those managed as outpatients were obtained from notification data (C Remondegui, Hospital San Roque, Jujuy, unpublished observations, 1994). 21 Estimates of transportation costs to the hospital were included in managerial costs, because managers often accompanied vehicles travelling to the areas where cholera patients lived in order to assess the situation. Medical and laboratory costs related to treatment of patients with cholera were also included ( Table 3) .
The base cost of hospitalization for cholera was calculated to be US$67.50 per day (Francisco Ryan, Ex-Sub-Secretarío de Salud Pública, Salta, personal communication, November 1994). Managerial costs per cholera case were obtained from Jujuy 20 and adjusted for Salta because Salta had no such data available. Additional managerial costs in Salta consisted of two helicopter trips each month for medical personnel to the cholera outbreak area (Francisco Ryan, Salta, personal communication, November 1994). These helicopters were not used prior or subsequently in medical work. Costs of antibiotics, rehydration solutions and medical supplies were obtained (Gregorio Mitelman, Director Farmacía, Salud Pública, Salta, personal communication, November 1994) and total costs were based on the amount of supplies used. 20 The Ministry of Health of Jujuy calculated medical therapy for one case of cholera to be US$228.50. Each faecal culture cost US$0.99 (Ana G B de Bojarski, Nélida J Molina, Laboratorio Bacteriología, Salta, personal communication, November 1994). Additional laboratory tests cost US$ 1.50 per hospitalized-day (Francisco Ryan, Salta, personal communication, November 1994).
The yearly US-Argentine exchange rate has been relatively stable at 0.9995-0.9905 from 1991 to 1994; 22 inflation has also been stable from 1992 to 1994. 22, 23 However, the 1992 and 1993 summer-outbreak costs were discounted by 5% compared to the 1994 costs.
Estimation of the Cost of Adding CVD 103-HgR Vaccine as a Cholera Control Measure
The National Health Promotion Programme is responsible for immunizing the paediatric and adult populations (e.g. tetanus vaccine to adults). Since a reliable infrastructure (i.e. health posts staffed by qualified nurses) exists for delivery of vaccines, we assumed modest administrative costs beyond the cost of the vaccine. We assume 80 vaccine doses could be administered and recorded per hour by one staff member of the Ministry of Health. Assuming 10 staff mobilized for short periods of time, 6000 vaccine doses can be administered per day (7.5 h per day for vaccination and recording). In the first year, 299 728 doses are to be given over 50 days. In the second and third years, 59 946 doses will be administered each year, over a total of 20 days. The salary per rural staff member is US$15.72 per day (Carmen M de Arquiza, Salta, personal communication, November 1994). Therefore, the total salary bill is US$11 004 for the 3 years. Publicity and recording material costs are estimated at US$35 000 for the 3 years and transportation costs at US$50 710. We assumed 400 reusable ice chests and 419 600 disposable cups would be needed, at a cost of US$10 per chest and US$0.01 per cup, this yields a total cost of US$8196 for the 3 years. The total administrative cost is estimated at US$104 910. For 419 620 doses to be given (100% coverage), this is an additional US$0.25 per dose. Assuming a cost of US$1.25 for the vaccine, the total cost is US$1.50 per dose. Numerous studies have examined the safety of CVD 103-HgR, in children and adult vaccinees in developing and more developed countries. [24] [25] [26] [27] [28] The vaccine has been shown to be well tolerated with no increases in diarrhoeal episodes or other adverse gastrointestinal reactions among vaccine compared with placebo recipients. [24] [25] [26] [27] [28] 
RESULTS

Cost Analysis
We calculate that the direct costs for management of a cholera case in Salta are US$626 and in Jujuy US$611, giving an average cost of US$622 per case (Table 3) . Cases in Salta have a higher cost because helicopters were used for transporting some patients and personnel, and antibiotic costs in the first outbreak were higher because of the initial setting up costs for the area health posts (Carmen M de Arquiza, Salta, personal communication, November 1994). Taking into consideration a 5% discounted cost for the first and second outbreaks, the overall cost per cholera case is US$602.
Base Case Model
The use of CVD 103-HgR prevents 1265 cases of cholera over the 3-year period ( Table 4 ). The conservative assumption of 75% vaccine coverage, 75% vaccine efficacy and a cost of US$602 per case, would result in a total savings of US$132 100, for a break-even point (i.e. cost/benefit ratio of 1.0) of US$1.81. Using a vaccine efficacy as low as 65% and vaccine coverage of 75% in the base case, vaccine use still proved to be cost-beneficial at US$1.57/dose of vaccine. Table 2 shows the number of cases of cholera that would occur in the target population over 3 years at three cholera incidences in the absence of vaccination. At the calculated cost of US$602 per case, the expenditures by the Ministries of Health of Salta and Jujuy for treatment of these cases would be US$812 098, US$1 082 998, or US$1 624 196 in the three scenarios.
Sensitivity Analysis
The number of cases that would be prevented by programmed use of CVD 103-HgR vaccine would range considerably, depending on the annual incidence, the degree of vaccine coverage of the targeted population, and the level of vaccine efficacy. The calculated numbers of cases prevented under these various conditions are shown in Table 4 . With vaccination coverage ranging from 75% to 90% and 3-year vaccine efficacy ranging from 60% to 85%, the break-even point (i.e. cost/benefit ratio of 1.0) was calculated. This represents the cost per dose of vaccine such that vaccine cost would not exceed the costs of cholera treatment in the absence of vaccination (Table 5) . We also calculated total savings (or losses) to the Ministry of Health from use of vaccine under the various conditions if vaccine cost US$1.50 per dose. The annual incidence of cholera had a marked effect on the cost benefit of vaccine use, being a good investment at the high annual incidence of 3.0 per 1000. In contrast, variations in the range of coverage of vaccination from 75% to 90% or in vaccine efficacy from 60% to 85% did not substantially affect the impact of a vaccination campaign. DISCUSSION AND CONCLUSION Argentina represents an interesting situation for conducting a cost-benefit analysis of the new oral attenuated cholera vaccine, CVD 103-HgR. First, Argentina COST-BENEFIT ANALYSIS OF CHOLERA VACCINE USE 217 is a country where some segments of the population live in underprivileged conditions typical of less-developed countries while others live in conditions typical of a developed country. Second, despite these pockets of poverty, the central government has instituted a sophisticated infrastructure for transport and treatment of cholera patients. This results in a high treatment cost per patient, typical of any industrialized country setting where a case of cholera gravis is managed. Third, the National Ministry of Health maintains a credible infrastructure that allows immunization of target groups of varying ages. Therefore, the means exist to deliver CVD 103-HgR to targeted populations. Fourth, it is possible to accurately estimate the financial burden borne by the Ministry of Health with respect to the treatment of cholera. Fifth, CVD 103-HgR is conducive to large-scale use because of its single-dose schedule and practical formulation. Finally, the National Ministry of Health has been willing to consider the purchase and implementation of cholera vaccine if the need continues (i.e. if cholera outbreaks continue to occur) and if a cost-benefit analysis provides a convincing argument in favour of programmed use of the new cholera vaccine. Prior cost-benefit analyses have considered the potential use of parenteral or oral killed cholera vaccines. [24] [25] [26] [29] [30] [31] These analyses involved endemic cholera occurring in Bangladesh where no infrastructure for immunizing older children and adults exists and the cost per treated case of cholera gravis is exceedingly low. Moreover, the oral killed vaccine requires that at least two doses be administered and length of efficacy may be shorter than for CVD 103-HgR. These conditions shift the balance against a role for vaccination.
A similar cost-benefit analysis was conducted in Santiago, Chile for evaluating the use of the Haemophilus influenzae type b conjugate vaccine. 32 The authors concluded that immunization represents a cost-effective public health intervention for preventing H. influenzae type b disease in Chilean children. In countries with limited resources, cost-benefit analyses can provide helpful information to public health decision makers who must make difficult choices.
The actual benefit of vaccination was undoubtedly underestimated in this analysis in Argentina since only the medical costs are considered. The true overall economic costs of the cholera epidemics in northern Argentina are much greater because of marked declines in tourism (parts of northern Argentina are popular tourist areas) and in the sale of agricultural products. These economic losses greatly exceed the treatment costs incurred. 29 Less significant indirect losses due to lost man-hours of work due to illness were also not considered. Additionally, lost productivity because of time taken from work to receive vaccination and any time lost due to vaccine side-effects were not considered. Since the health clinics are located where the workers reside and CVD 103-HgR vaccination has minimal side-effects, we believe that these costs would not alter our conclusions. Our base case incorporates the actual annual incidence rate for cholera, a conservative level for vaccine coverage (given a rate of 93% in the infant population for BCG vaccination), and a conservative estimate for vaccine efficacy (given results of volunteer and field studies). Nevertheless, our base case analysis demonstrates that CVD 103-HgR, when delivered to the confined high-risk population of northern Argentina, can be an important part of cholera control activities in that region. Vaccination would prevent 1265 cases of cholera for discounted savings to the Ministry of Health of US$132 100.
